These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Lange S; Mueller SC; Altmann S; Dahlhaus M; Drewelow B; Freund M; Junghanss C Bone Marrow Transplant; 2008 Apr; 41(7):667-74. PubMed ID: 18084333 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Wakahashi K; Yamamori M; Minagawa K; Ishii S; Nishikawa S; Shimoyama M; Kawano H; Kawano Y; Kawamori Y; Sada A; Matsui T; Katayama Y Int J Hematol; 2011 Aug; 94(2):193-202. PubMed ID: 21751082 [TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611 [TBL] [Abstract][Full Text] [Related]
32. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696 [TBL] [Abstract][Full Text] [Related]
39. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
40. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Kornblit B; Maloney DG; Storer BE; Maris MB; Vindeløv L; Hari P; Langston AA; Pulsipher MA; Bethge WA; Chauncey TR; Lange T; Petersen FB; Hübel K; Woolfrey AE; Flowers ME; Storb R; Sandmaier BM Haematologica; 2014 Oct; 99(10):1624-31. PubMed ID: 25085357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]